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Systemic inﬂammatory rheumatic diseases, such as rheumatoid
arthritis (RA), are associatedwith increased cardiovascularmortality, on
account of the high prevalence of ischemic heart disease and accelerated
atherosclerosis, compared with age- and sex-matched controls [1]. The
higher risk of cardiovascular disease (CVD) in RA patients seems to be
independent of traditional cardiovascular risk factors. Different patho-
genic mechanisms including pro-oxidative dyslipidemia, insulin resis-
tance, prothrombotic state and hyperhomocysteinemia have been
described [2]. However, immune activation is a key mechanism that
promotes structural and functional abnormalities of the vascular bed.
Arterial stiffness, usually measured by pulse-wave velocity analysis, is
considered a marker of subclinical vascular disease and increased CVD
risk, and it is markedly abnormal in patients with RA [3,4]. Large left
ventricular (LV)masshas also been associatedwith RA, suggesting a link
between chronic inﬂammation and LV hypertrophy [5].We investigated
the elastic properties of the aorta and systo-diastolic function in RA
patients without CV disease, compared with healthy controls.
In our study, RA was diagnosed according to American College of
Rheumatology criteria [6]. Disease activity was assessed at time of
cardiological evaluation using a composite index, calledDAS44, including
swollen and tender joint count (on 44 joints), global health assessment
and ESR value. The patients had a cardiological examination, 12-lead
electrocardiography (ECG) and two-dimensional and Doppler trans-
thoracic echocardiography. The exclusion criteria of the study were:
(a) arterial hypertension (blood pressure N140/90 mmHg in more than
three consecutive readings or use of any hypotensive drugs);
(b) diabetes; (c) smoke; (d) symptomatic dyspnea or chest pain;
(e) use of any cardiovascular drugs (including statins); (g) any previous
myocardial infarction, surgical or percutaneous revascularization, a
positive ECG result, perfusion or echocardiographic exercise or pharma-
cological stress test; (h) more than mild aortic or mitral regurgitation
and/or stenosis; (i) any previous surgical or interventional cardiac or
vascular procedure; (l) familial hypercholesterolemia; (m) any genetic
cardiovascular disease (including cardiomyopathy orMarfan syndrome).
Patients were matched to normal controls for age, sex and ethnicity.
The 44 selected RApatients have amean age of 55 years (±14 years)
and mean duration of RA 9.6 years (±7.6 years). CRP was high at the
time of the cardiac evaluation in 19 patients (43.2%). Rheumatoid factor
and anti-cyclic citrullinatedpeptide (anti-CCP) antibodieswere found in
73.8% and 62% of subjects, respectively. Themean disease activity index,
assessed using the DAS44 score, was low (mean 2.4±1.6). Prednisone,
methotrexate, or anti-TNF agentswere currently being or had been used
by respectively 95%, 80.5% and 63.4% of the patients. Table 1 shows their
baseline demographic and cardiovascular data.
Compared with age- and sex-matched controls, the RA patients
had greater posterior wall and septal thickness, but no other
differences from controls in terms of LV end-diastolic/end-systolic
diameter or ejection fraction (Table 2). As a consequence, RA subjects
had a greater LV mass (155±47 vs. 140±31 g; p=0.01), LV mass
index (mean 140±31 vs. 92±25 g/m2 pb0.001) and indexing to
height in meters to the power 2.7 (43±12 vs. 31±10 g/m 2.7;
p=0.0043) than controls.
We also found lower mean aortic strain (7.7±3% vs. 13±5%;
pb0.001) and distensibility (2.8±1.2 vs. 5.4±2.6 cm2dyn−1×10−6;
pb0.001) with a highermean stiffness index (9.2±6.05 vs. 5.06±2.9;
pb0.001) in RA cases, compared with controls. There was also a
signiﬁcant difference between RA patients and controls in term of
E/A (1.1±0.7 vs. 1.7±0.6, pb0.001), deceleration time (225±56 vs.
190±50 ms, p=0.004) and E/E′ (10.3±5.5 vs. 7.3±3.5, pb0.01).
A comparison of aortic distensibility and other morphological and
functional cardiac parameters showed no signiﬁcant association
between LV mass with aortic distensibility, aortic strain and stiffness.
In addition, RA duration, disease activity index (DAS 44) and CRP did
not correlate with either LV mass or aortic elastic properties.
Increased aortic stiffness and decreased aortic distensibility
were closely associated with diastolic ﬁlling indexes measured by
conventional and tissue Doppler echocardiography. In particular, we
found a signiﬁcant association between aortic distensibility, E/A
(pb0.001) and E′ (p=0.013), aortic stiffness and deceleration time
(p: 0.01) and between aortic strain, E/A (pb0.001) and E′ (p=0.02).
After adjustment for age and systolic blood pressure, at multivariable
stepwise regression analysis, RA (pb0.0001) and systolic blood
pressure (p=0.022) were independently related with distensibility,
only RA was independently related with stiffness (p=0.0003) and
with strain (pb0.0001). Age (p=0.0004) and RA (p=0.0014) were
independently related with E/A, while only RA (p=0.0069) was
independently related with E/E′. RA (p=0.00154) and age
(p=0.0076) were independently related with DT.
At a multivariable stepwise regression analysis, rheumatoid factor,
DAS, anti-CCP status were not related with aortic stiffness, distensibility,
LV mass. Stratifying cases on the basis of RA duration (more or less than
ten years), we also found no differences for LV mass and other elastic
properties of the aortic wall. When considering RA treatment, pre-
dnisone, methotrexate or anti-TNF alpha therapies were not related with
stiffness, distensibility, LV mass at multivariable regression analysis.
The results of this study are that, ﬁrst, patients with RAwithout CV
disease or any CV risk factors had an increase in LVmass and abnormal
elastic properties of the aorta (increased arterial stiffness, lower
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Table 1
Main-features of the rheumatoid arthritis patients and controls.
RA patients (n. 44) Controls (n. 35) p
Age (mean±SD) 57±15 56±10 ns
Sex (% female) 73% 71% ns
Systolic pressure mmHg (mean±SD) 130±11 128±11 ns
Diastolic pressure mmHg (mean±SD) 74±8 71±17 ns
Heart rate, beats/minute (mean±SD) 76±10 72±11 ns
Body surface area (mean±SD) 1.7±0.2 1.7±0.4 ns
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distensibility and strain) than controls. Second, these patients also had
signiﬁcant impairment of LV diastolic function and a close correlation
between this dysfunction and increased aorta stiffness.
The increased LV mass and stiffening of the aorta, even in patients
without hypertension or clinical CV disease, suggest that RA patients
might have a condition of preclinical atherosclerosis. Aortic elastic
properties are important determinants of LV systolic and diastolic
function and, in some cases, increased stiffness has been linked to
diastolic heart failure. Increased diastolic dysfunction in RA seems to
correlate with long disease duration. We found a correlation between
aortic stiffness, distensibility and diastolic ventricular dysfunction.
These two conditions probably inﬂuence the prognosis of RA patients
and provide a plausible mechanism for their increased cardiovascular
morbidity and mortality. Although our patients did not have active
disease at the time of cardiologic assessment, the longstanding
chronic systemic inﬂammatory state may accelerate the atherosclero-
tic process, increasing aortic stiffening and LV mass.
Further prospective studies are needed to establish whether
abnormal elastic aortic properties really correspond to an increased
risk of cardiovascular disease in RA.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology [7].
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We want to acknowledge Topatan and Başaran for their contribu-
tion toward a better understanding of the pathophysiology of antigen
carbohydrate 125 (CA125) in heart failure (HF) [1].
First, we want to clarify to the authors that longitudinal results
presented in our letter entitled "Antigen carbohydrate 125 in heart
failure: Not just a surrogate for serosal effusions?" were misinter-
preted and nomethodological issues are present in our calculation [2].
These results (which are also presented in ﬁgure 1 – see explanation
text at the bottom of the ﬁgure), were expressed as median
(interquartile range), and not as median (min-max range).
Second, ourdisagreementwith the above authors can be summarized
into twoaspects: 1) the role of CA125within the verycomplex andpoorly
understood pathophysiological cascade that ultimately leads to an
elevation of pro-inﬂammatory markers in acute heart failure syndromes
(AHF), and; 2) clinical usefulness of CA125 serum levels in HF.
There is plenty of evidence showing a signiﬁcant elevation in CA125,
proinﬂammatory markers as well as systemic volume expansion in AHF
[3–6].How these factors are inter-related is still amatterof controversy. Is
the mesothelial cells activation by volume expansion/serosal effusions
the main mechanism for triggering the production of CA125, or is it the
already heightened background inﬂammation in AHF that triggers the
activation of themesothelial cells, leading ultimately to CA125 elevation?
We believe that the amount of evidence available is insufﬁcient to dissect
the exact role of CA125 within the (most likely) multifactorial cascade
that ultimately leads to an elevation of pro-inﬂammatorymarkers inAHF.
Therefore, it seems unfair to conclude that CA125 is no more than a
simple surrogate for the presence of serosal effusions and mesothelial
stimulation.We cautiously have suggested thatCA125may increase inHF
patients, not only as a consequence of serosal effusion but, perhaps
Table 2
Left ventricular (LV) structure and function parameters in RA patients and controls.
RA patients (n. 44) Controls (n. 35) p
Septal thickness mm 10±1.2 9.3±1.2 0.02
Posterior wall thickness mm 8.9±1.2 8.2±1.2 0.01
LV end-diastolic dimension mm 47±7 47±4 0.93
LV end-systolic dimension mm 25±3.4 27±7 0.25
Ejection fraction % 62±7 64±4.4 0.26
LV mass, g 155±47 140±31 0.012
LV mass index, g/m2 140±31 92±25 b0.0001
LV mass index, g/m 2.7 43±12 31±10 0.0043
E/A 1.1±0.7 1.7±0.6 0.0003
DT msec 234±55 190±50 0.005
E/E′ 11±5.8 7.3±3.6 0.0034
AoS mm 3.2±0.4 3.05±0.4 0.01
AoD mm 3±0.4 2.7±0.4 0.0054
Distensibility cm2 dyn−1 10−6 3±1.2 5.4±2.7 b0.001
Stiffness index 8.3±4.5 5±2.9 0.002
Strain % 8.1±3.1 13±7 0.0003
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